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Deregulation of iron metabolism has been observed in patients with neurodegenerative
diseases. We have carried out a molecular analysis investigating the interaction between
iron specific gene variants [transferrin (TF, P589S), hemochromatosis (HFE) C282Y and
(H63D)], iron biochemical variables [iron, Tf, ceruloplasmin (Cp), Cp:Tf ratio and % of
Tf saturation (% Tf-sat)] and apolipoprotein E (APOE) gene variants in 139 Alzheimer’s
disease (AD), 27 Mild Cognitive Impairment (MCI), 78 Parkinson’s disease (PD) patients
and 139 healthy controls to investigate mechanisms of iron regulation or toxicity. No
difference in genetic variant distributions between patients and controls was found in
our Italian sample, but the stratification for the APOEε4 allele revealed that among the
APOEε4 carriers was higher the frequency of those carriers of at least a mutated TF P589S
allele. Decreased Tf in both AD and MCI and increased Cp:Tf ratio in AD vs. controls were
detected. A multinomial logistic regression model revealed that increased iron and Cp:Tf
ratio and being man instead of woman increased the risk of having PD, that increased
values of Cp:Tf ratio corresponded to a 4-fold increase of the relative risk of having MCI,
while higher Cp levels were protective for PD and MCI. Our study has some limitations:
the small size of the samples, one ethnic group considered, the rarity of some alleles
which prevent the statistical power of some genetic analysis. Even though they need
confirmation in larger cohorts, our data suggest the hypothesis that deregulation of iron
metabolism, in addition to other factors, has some effect on the PD disease risk.
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INTRODUCTION
It is now fairly well accepted that transition metals, such as iron
and copper, are involved in the pathogenesis of some neurodegen-
erative disorders, like Alzheimer’s disease (AD) and Parkinson’s
disease (PD). Specifically, an excessive iron accumulation has
been reported in neuritic plaques, neurofibrillary tangles and in
specific brain areas of patients with AD (Castellani et al., 2007).
Moreover, abnormal exchange of cortical zinc has been described
to link amyloid pathology with neuronal iron accumulation in
AD (Duce et al., 2010) and, more recently, some data show that
in AD, hippocampus damage occurs in conjunction with fer-
ritin iron accumulation (Raven et al., 2013). This evidence is in
disagreement with a recent meta-analysis, reported that iron is
not increased in the AD brain (Schrag et al., 2011). However,
neuroimaging in vivo as well as post-mortem examinations at
autopsy have demonstrated that increased nigral iron content
in patients with PD is a prominent pathophysiological feature
(Dexter et al., 1987; Graham et al., 2000; Kaur and Andersen,
2004; Zecca et al., 2004; Berg et al., 2006; Rhodes and Ritz, 2008;
Péran et al., 2010) and different findings suggest that decreased
levels of serum ceruloplasmin may specifically exacerbate nigral
iron deposition in PD patients (Bharucha et al., 2008; Jin et al.,
2011, 2012; Martinez-Hernandez et al., 2011). We recently per-
formed a meta-analysis of the published studies on serum to
elucidate the possible role of systemic metabolism of iron in
the risk for developing PD. Our results showed no change of
iron levels in PD patients, but evidenced a higher heterogeneity
that, although reducing the weight of result, stresses the atten-
tion on complex homeostasis of iron that play a crucial role in the
pathogenesis of PD (Mariani et al., 2013).
The brain iron content increases with advancing age (Zecca
et al., 2001) and could lead to enhanced oxidative stress through
protein and lipid peroxidation, and DNA oxidation, causing,
eventually, cellular and neuronal damage or death (Halliwell,
1992; Salvador et al., 2010). Brain iron homeostasis is regulated
by different factors (Levenson and Tassabehji, 2004; Johnstone
and Milward, 2010), among which the transferrin (Tf) and the
hemochromatosis (HFE) proteins seem to play a key role. These
proteins, encoded by the TF and HFE genes (Barry et al., 2005),
compete for binding the Tf receptor (Tfr) (Feder et al., 1998).
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Specifically, HFE is a membrane protein which controls iron
absorption by regulating the affinity of Tfr on the cell membrane.
HFE mutations cause hereditary hemochromatosis, a recessive
autosomal disorder, with an increased absorption of dietary iron
and its consequent overdeposition in tissues and organs (Phatak
et al., 2002; Ajioka and Kushner, 2003; Barry et al., 2005).
Concerning TF gene, there are different genetic variants due
to amino acids substitution in the polypeptide chain. The TF
C is the most common in Caucasian population and it has at
least 16 variants (C1–C16). The C1 variant is the most preva-
lent (95%) and its encoding polymorphic gene has two allelic
variants that produce transferrin C2 (proline in position 589
replaced by a serine, P589S). Both TF C2 (rs1049296) and the
2 HFE, C282Y (rs1800562) and H63D (rs1799945) gene variants,
have been investigated as potential risk factors for neurodegen-
erative disorders. Studies analyzing the association between HFE
mutations and AD came to different conclusions regarding the
hypothesis that H63D mutation may anticipate the disease onset
in sporadic AD (Sampietro et al., 2001; Candore et al., 2003).
Still other authors evaluated the possible interaction between
TF C2 and HFE C282Y, supporting the hypothesis that iron
transport and regulation play a role in AD (Kauwe et al., 2010;
Lehmann et al., 2012). Some authors suggested that the com-
bination of TF C2 and HFE C282Y can lead to an excess of
redox-active iron even in mild cognitive impairment (MCI)
(Robson et al., 2004). Data available for PD, reported that the
common variants in HFE might be a risk factor also for this
disease (Guerreiro et al., 2006), even though the same authors
did not confirm the risk for AD. Taken together these studies,
although not always providing concordant results, seem to sup-
port the hypothesis that iron metabolism plays a role in some
neurological disorders. To improve knowledge about the mech-
anism of iron regulation and toxicity in living AD, MCI, and
PD subjects, a molecular analysis investigating the interaction
between iron specific gene variants, iron biochemical assess-
ments and apolipoprotein E (APOE) gene risk factor is reported
herein.
MATERIALS AND METHODS
SUBJECTS
The subject sample consisted of 383 participants: 139 healthy con-
trols (female (F)% 68, age mean ± standard deviation 63 ± 12
years), 139 AD (F% 71, age 73 ± 8), 27 MCI (F% 52, age 71 ± 8)
and 78 PD patients (F% 33, age 67 ± 10; Table 1). Both patients
and control subjects were recruited by two specialized demen-
tia care Centers in Rome, Italy: the Department of Neuroscience
of San Giovanni Calibita—Fatebenefratelli Hospital, and the
Department of Neurology of Campus Bio-Medico University.
The diagnosis of “probable AD” was posed according to
NINCDS–ADRDA criteria (McKhann et al., 1984; Dubois et al.,
2007). AD patients had a MMSE score ≤25 (Folstein et al., 1975).
PD patients were diagnosed according to the UK PDS Brain Bank
Criteria for the diagnosis of PD (Gibb, 1988) and the disease
severity was classified on the basis of Unified Parkinson’s Disease
Rating Scale (UPDRS).
The inclusion and exclusion criteria for MCI were based on
previous seminal studies (Albert et al., 1991; Petersen et al.,
Table 1 | Demographic characteristics and mean values ± SD
(standard deviation), or median value (minimum-maximum) of the
biochemical parameters in study in controls, AD, MCI and PD
patients.
Controls AD MCI PD
Age 63 (±12) 73 (±8) 71 (±8) 67 (±10)
sex (%F) 68% 71% 52% 33%
APOE (%ε4) 11.4% 31.60% – –
Cp (mg/dL) 27.5 (10–60.2) 26.8 (±5.3)
p = 0.9
24.4 (±5.1)
p = 0.1
27.7 (±5.1)
p = 0.8
Iron (μg/dL) 76.3 (11–190) 73.0 (11–441)
p = 0.9
83.0 (±27.6)
p = 0.6
74.84 (12–178)
p = 0.5
Tf (g/L) 2.6 (1.6–4.8) 2.4 (±0.4)
p < 0.001
2.4 (±0.6)
p = 0.04
2.7 (±0.5)
p = 0.9
Cp:Tf
ratio *10(−2)
10.3 (5–21.0) 11.4 (±2.7)
p = 0.002
10.7 (±2.7)
p = 0.6
10.8 (±2.3)
p = 0.5
Tf saturation
(%)
24.1 (1.8–76) 24.4
(2.25–126.0)
p = 0.469
27.3
(10.9–51.8)
p = 0.652
21.7
(2.5–58.8)
p = 0.203
1999, 2001; Portet et al., 2006), defining elderly persons who do
not meet the criteria for a diagnosis of dementia, with objec-
tive cognitive deficits, especially in the memory domain. Criteria
were as follows: (I) objective memory impairment on neuropsy-
chological evaluation, as defined by performances P1.5 standard
deviation below the mean value of age and education- matched
controls for a test battery including Busckhe–Fuld and Memory
Rey tests; (II) normal activities of daily living as documented by
the history and evidence of independent living; and (III) clini-
cal dementia rating score of 0.5. The exclusion criteria for MCI
included: (I) mild AD; (II) evidence of concomitant demen-
tia such as frontotemporal form, vascular dementia, reversible
dementias (including pseudo-depressive dementia), fluctuations
in cognitive performance, and/or features of mixed demen-
tias; (III) evidence of concomitant extra-pyramidal symptoms;
(IV) clinical and indirect evidence of depression as revealed by
Geriatric Depression Scale scores higher than 13; (V) other psy-
chiatric disorders, epilepsy, drug addiction, alcohol dependence,
and use of psychoactive drugs including acetylcholinesterase
inhibitors or other drugs enhancing brain cognitive functions;
and (VI) current or previous uncontrolled or complicated sys-
temic diseases (including diabetes mellitus) or traumatic brain
injuries (Rossini et al., 2008).
The control sample consisted of healthy volunteers with no
clinical evidence of neurological or psychiatric disease. Exclusion
criteria for both patients and controls were conditions known
to affect copper metabolism and biological variables of oxidative
stress (e.g., diabetes mellitus, inflammatory diseases, recent his-
tory of heart or respiratory failure, chronic liver or renal failure,
malignant tumors, and a recent history of alcohol abuse). All
individuals included in this study are Caucasian. The study was
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approved by the local IRB and all the subjects involved or legal
guardians signed their informed consent.
GENOTYPING
Genomic DNA from fresh whole blood was prepared using the
conventional method for DNA isolation (QLAamp DNA Blood
Midi kit). Genotyping of SNPs rs1800562, rs1799945, rs1049296
were achieved by the TaqMan allelic discrimination assays from
Applied Biosystems Inc. (Foster City CA). The predesigned
SNPs genotyping assays ID are C_1085595_10, C_1085600_10,
C_7505275_10 (Applied Biosystems). The total reaction vol-
ume per well was 20μL, including 5 ng genomic DNA, 1μL
TaqMan SNP genotyping assay (containing two PCR primers
and two dye (VIC or FAM) labeled TaqMan MGB probes) and
10μL TaqMan Universal PCR Master Mix (Applied Biosystems),
according to the manufacturer’s manual. PCR was performed at
95◦C for 10min and 40 cycles at 95◦C for 15 s and 60◦C for
1min. The samples were amplified, read, and analyzed using the
ABI Prism 7900HT Sequence Detection Systemand ABI Prism
SDS 2.4 software. Two blank controls in each 96-well-plate were
used for the assay quality control. APOE genotyping was per-
formed according to establish methods (Hixson and Vernier,
1990).
BIOCHEMICAL INVESTIGATIONS
Patients’ fasting blood samples were collected in the morning and
serumwas rapidly stored at−80◦C. Ceruloplasmin (Cp) was ana-
lyzed by immunoturbidimetry assay (Horiba ABX, Montpellier,
France) (Wolf, 1982). Iron was analyzed using Ferene, a lig-
and capable of forming chelates with iron (II), (Higgins, 1981)
and transferrin by mixing human serum with the antibody
solution and measuring the resulting immune complexes by
immunoturbidimetry assay (Skikne et al., 1990). The percent-
age of transferrin saturation (% transferrin-sat) was calculated by
dividing serum iron by the total iron-binding capacity (TBC =
Transferrin in mg/dL ∗1.25) and multiplying by 100. The ferritin
was analyzed by immunoturbidimetry assay enhanced with latex
(Simo et al., 1994). All reagents were ABX Pentra from Horiba
ABX (Montpellier, France). Finally, we measured the Cp:Tf ratio
[Cp/Tf ∗10 (−2)]. All biochemical measures were automated
on a Cobas Mira Plus (Horiba ABX, Montpellier, France) and
performed in duplicate.
STATISTICAL ANALYSIS
Demographic and clinical characteristics in our patient and con-
trol samples were described either in terms of mean ± SD if
quantitative, or in terms of proportions. Student’s t-test and the
chi-square (χ2) test, or a non parametric test when appropriate,
were used to compare separately each diagnosis (AD, MCI and
PD) group vs. healthy controls. The effects of both age and sex
were considered in all statistical analyses. Diagnosis groups were
compared using ANCOVA models adjusting for genetic variable
as well as age and sex. AMultinomialMultiple Logistic Regression
model was applied, considering the control group as the reference
category, to evaluate the effects of the biological and genetic vari-
ables on the probability of being AD or PD or MCI. All tests were
interpreted at the 0.05 level of significance. SPSS 16.0 software was
used for all statistical analyses.
RESULTS
We screened participants for C282Y (rs1800562), H63D
(rs1799945) HFE gene and P589S (rs1049296) TF gene
mutations in order to test their association with AD, MCI and
PD. Gene frequencies were in Hardy-Weinberg equilibrium in
each group.
The analysis revealed that there was no significant differ-
ence in genotype or allele frequencies of C282Y and H63D
(Table 2) HFE gene variants among AD, MCI and PD sub-
jects vs. healthy controls, though a C282Y mutation higher fre-
quency approached significance in the MCI group (p = 0.06;
Table 2). The analysis of the TF C2 polymorphism revealed that
the wild type genotype was carried by 64% of healthy con-
trols vs. 54% of AD patients (p = 0.08; Table 2). Finally, the
stratification for the APOEε4 allele revealed a significant dif-
ference in the frequency of the mutated genotypes of the TF
gene between APOEε4 carriers and non-carriers (p = 0.001;
Table 3).
Table 2 | Genotype and allelic frequencies for HFE (C282Y, H63D) and
TF (P589S) mutations in controls, AD, MCI, and PD patients.
Controls AD patients MCI patients PD patients
HFE C282Y
Wt GG 137 (98.6%) 138 (100%) 25 (92.6%) 70 (95.9%)
mutation GA\AA 2 (1.4%) – 2 (7.4%) 3 (4.1%)
p = 0.1 p = 0.06 p = 0.2
allele G 276 (99.3%) 276 (100%) 52 (96.3%) 143 (98%)
allele A 2 (0.7%) – 2 (3.7) 3 (2%)
p = 0.08 p = 0.06 p = 0.2
HFE H63D
wt CC 99 (71.2%) 99 (71.7%) 21 (77.8%) 53 (68.8%)
mutation CG\GG 40 (28.8%) 39 (28.3%) 6 (22.2%) 24 (31.2%)
p = 0.4 p = 0.5 p = 0.5
allele C 236 (84.9%) 237 (85.9%) 48 (88.9) 130 (84.4%)
allele G 42 (15.1%) 39 (14.1%) 6 (11.1%) 24 (15.6%)
p = 0.7 p = 0.7 p = 1
TF  C2
wt CC 77 (65.3%) 59 (54.1%) 19 (70.4%) 47 (60.3%)
mutation CT\TT 41 (34.7%) 50 (45.9%) 8 (29.6%) 31 (39.7%)
p = 0.08 p = 0.4 p = 0.2
allele C 194 (82.2%) 163 (74.8%) 45 (83.3%) 121 (77.6%)
allele T 42 (17.8%) 55 (25.2%) 9 (16.7%) 35 (22.4%)
p < 0.0001 p = 0.8 p = 0.3
Table 3 | Genotype associated with wild type TF C2 in AD patients
with (APOEε4+) and without (APOEε4−) Apoε4 allele.
TF C2 p-value
CC CT\TT
APOEε4+ 12 22
APOEε4− 47 29 0.01
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We measured iron, transferrin, ceruloplasmin, and calculated
the Cp:Tf ratio and%Tf saturation in the whole study population.
Some of these variables were not normally distributed and so we
applied a Mann-Whitney non parametric test and these data are
presented as median (min-max) in Table 1. We found a signifi-
cant reduction in the concentration of Tf both in AD and in MCI
and a significant increase of the Cp:Tf ratio in AD patients than
in controls (Table 1). Conversely, adjusting for age and sex in an
ANCOVAmodel we observed that there was a significative simple
effect of the diagnosis factor on Tf values [p = 0.008, F(3, 274) =
4.055]; in particular only the estimated parameter for AD diag-
nosis resulted significative (parameter estimate = −0.197, t =
−2.124, p = 0.035), a significant simple effect of age was evident
too [p = 0.004, F(1, 274) = 8.210]. The simple effect of diagno-
sis was significant on Cp:Tf ratio (p = 0.014, F = 3.603, df =
3,255) but it was due to difference between MCI and controls
(parameter estimate = −1.666, t = −2.217, p = 0.028). Also the
simple effect of age [p = 0.011, F(1, 255) = 6.626) and of sex [p =
0.002, F(1, 255) = 10.060] were significant on Cp:Tf ratio.
Then, we again performed the ANCOVA analysis taking into
account factors like diagnosis, age, sex and genetic variants and
their possible interaction on concentration of biochemical vari-
ables under study. The analysis revealed a significant influence of
the interaction between sex andHFE on iron concentrations [p =
0.038; F(1, 243) = 4.3524] and, always on iron concentrations,
a significant simple effect of sex [p = 0.023; F(1, 243) = 5.212],
age [p = 0.028 F(1, 243) = 4.876]. The analysis reconfirmed the
previous results on Cp:Tf ratio while the effect ofHFEwas not sig-
nificant (p > 0.20). The effect of age was significant [p = 0.016,
F(1, 264) = 5.886] on the Tf values and also the effect of diagno-
sis factor [p = 0.008, F(3, 264) = 4.038]. Finally, we observed the
only significant effect of sex factor on Cp concentrations [p <
0.001, F(1, 301) = 35.886]. The probability of having AD, PD or
MCI was estimated with a multinomial logistic regression model
considering the diagnosis as the dependent variable and the bio-
chemical and genetic markers, as well as sex and age, as the
independent variables and the control group was set as the ref-
erence category. These statistical analyses confirmed age as the
main risk factor: the increase of age (1 year) increased of 14%
the risk of being AD (p < 0.001. OR= 1.14; 95% C.I. 1.07–1.21).
Concerning PD, increased of 1μg/dL of iron (p = 0.031; OR =
1.06; 95% C.I. 1.01–1.11), of Cp:Tf ratio (p = 0.016; OR = 2.9;
95% C.I. 1.22–6.75) as well as being man instead of woman (p <
0.001; OR= 5.20; 95%C.I. 2.14–12.66) resulted in a higher risk of
havingPD,while the increase of Cp concentration (1mg/dL) was a
protection factor (p = 0.042; OR = 0.72; 95% C.I. 0.53–0.99). In
MCI, we observed that increasing values of Cp:Tf corresponded
to a 4-fold increase of the relative risk of having MCI (p = 0.013;
OR = 4.27; 95% C.I. 1.374–13.32), and conversely that higher Cp
levels resulted as a protection factor (p = 0.009; OR = 0.53; 95%
C.I. 0.32–0.85).
DISCUSSION
Several studies investigated the role of the principal variants of
HFE and TF genes on the risk of having neurodegenerative dis-
orders, in particular AD, PD and MCI even though separately.
The results reported are often controversial and this inconsistency
suggests that, beside the complex genetic etiology, additional
interactions can contribute to the disease, as for example, envi-
ronmental factors, age, sex, and metal ion involvement or oxida-
tive stress. Considering the current literature, we examined the
contribution of HFE and TF mutations in PD, AD and MCI test-
ing if single gene variants have an impact on iron metabolism.
Even though our results don’t support the hypothesis that these
mutations are a genetic risk factor for Italian cohort they have
been reported to have a strong effect on the disease risk in
several populations (Buchanan et al., 2002; Combarros et al.,
2003; Robson et al., 2004). Moreover, a direct significant synergy
between the TF C2 allele and the GA and AA genotypes of C282Y
of the HFE gene on the disease risk has been reported by Robson
(Robson et al., 2004) and recently confirmed by two additional
studies carried out on very large subject samples (Kauwe et al.,
2010; Lehmann et al., 2012). Some of ours negative results can
be explained on the basis of the fact that the C282Y HFE muta-
tion is very rare in the Italian population (Sampietro et al., 2001),
and specifically, in our AD sample there was no patient carrier of
the homozygous genotype. Interestingly, while this mutation was
rare also in the PD sample, the direct comparison between AD
and PD revealed that PD patients had a significantly higher fre-
quency. Even concerning these data, literature is controversial, in
fact, Guerreiro and colleagues (Guerreiro et al., 2006) described
a significant increase of the prevalence of homozygous C282Y
carriers in PD patients compared with healthy controls but not
in AD, concluding that it could be a risk factor for PD but not
for AD in the Portuguese population. This result is confirmed by
some (Dekker et al., 2003) but not all studies (Borie et al., 2002;
Buchanan et al., 2002).
We found an interaction between TF C2 and APOEε4 alleles
(Table 3), evidence already described by some authors (Namekata
et al., 1997) but not confirmed by others (Marklova et al., 2012)
We observed that in AD patients with at least one copy of the
APOEε4 allele, the frequency of the CT or TT genotype of TF C2
was almost twice as that in the remaining AD non-APOEε4 allele
carriers. The underlying mechanisms of this interaction remain
unknown but the effect of the combination between TF C2 and
APOEε4 in AD patients is a meaningful question that deserves
further studies.
Concerning the biochemical analysis, we observed a significant
decrease of Tf concentration in AD and MCI patients compared
with healthy control subjects and an increase of the Cp:Tf ratios
in AD in line with previous studies (Squitti, 2012). This find-
ing is in line with the derangements of iron metabolism widely
described in AD brain and also in MCI (Lavados et al., 2008;
Smith et al., 2010). Altered patterns of TF gene expression and of
Cp levels and activity in the AD brain have been reported (Loeffler
et al., 1994, 1996; Castellani et al., 2007). Cp and Tf interact to
limit concentrations of labile (“free”) iron and copper species,
and thus play an important role in antioxidant defense in serum.
More precisely, the Cp:Tf system is involved in counteracting
oxidative stress generated in different body districts by regulating
the serum capacity to sequester exchangeable transition metals,
which are particularly prone to partake in oxidative stress chain
reactions (Kozlov et al., 1984; Hubel et al., 1996; Altamura et al.,
2009).
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The multinomial logistic regression model presented revealed
the significant influence of iron and of Cp:Tf values on the
probability of having PD, sustaining that an alteration on iron sys-
tem is involved in the development of this disease. These results
demonstrate that iron dysfunction has an effect on the PD risk,
even though this diagnosis has not effect on the mean value
of iron measured in general circulation, as demonstrated in a
recent meta-analysis (Mariani et al., 2013) and confirmed by the
ANCOVA results reported in our current study.
The effect of sex on iron levels in relation with PD is com-
plex. In fact, even though in our recent meta-analysis (Mariani
et al., 2013) we didn’t find a significant effect of being women on
iron circulating levels, the replication study reported in the same
study (Mariani et al., 2013) pointed out that women had higher Tf
serum levels, which can possibly modify iron internalization and
tissue storage. In current study, we have again found a sex effect
on the disease risk.
The activation of the Cp:Tf antioxidant system appears a
mechanism of the early stages of some neurodegenerative dis-
eases. Current result describes a 4-fold increased risk of having
MCI in those subjects with higher values of the Cp:Tf ratio.
This fact was document in a previous study demonstrating an
increment in the ratio of serum copper to non-heme iron levels
predicting which subjects with MCI would progress to demen-
tia vs. those that would remain cognitively stable (Mueller et al.,
2012).
Higher systemic Cp concentrations seem a protective factor
for both MCI and PD subjects and our results about PD are
in accord with recent findings reporting a loss of Cp ferroxi-
dase activity in the substantia nigra of PD cases suggesting that
intravenous Cp may have therapeutic potential in PD (Ayton
et al., 2012). This evidence is consistent with the role of Cp that,
oxidizing Fe (II) to Fe (III) allows iron binding to Tf and its
mobilization from iron tissue storage. More specifically, the result
that increased Cp concentrations are a protecting factor for PD is
in line with the evidence that CP mutations have been associated
with increased deposits of iron in SN (Hochstrasser et al., 2004,
2005).
A result worthy of interest is the effect of interaction between
sex andHFE. As detailed in the ANCOVAmodel, the presence on
an HFE gene mutation (H63D or C282Y) results in an increased
absorption of iron in men. A “disease effect” seems essential to
explain this relationship, since increased iron levels cannot be
ascribed to the HFE change alone, but rather it is caused by the
synergy between being man and HFE change on iron levels, sus-
taining previous results (Fargion et al., 1992; Niederau et al., 1996;
Adams et al., 1997).
Our study has some limitations that need to be taken into
account: the small size of the sample, and specifically the small
number of MCI subjects included; one ethnic group considered;
the rarity of some alleles which prevent the statistical power
of some genetic analysis. Even though they need confirmation
in larger cohorts, our data suggest that deregulation of iron
metabolism, in addition to other factors, has some effect on the
PD disease risk.
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